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Crucial Role of Mesangial Cell-
derived Connective Tissue Growth 
Factor in a Mouse Model of Anti-
Glomerular Basement Membrane 
Glomerulonephritis
Naohiro Toda1, Kiyoshi Mori2,3, Masato Kasahara4, Akira Ishii1, Kenichi Koga1, Shoko Ohno1, 
Keita P. Mori1, Yukiko Kato1, Keisuke Osaki1, Takashige Kuwabara1,5, Katsutoshi Kojima6, 
Daisuke Taura6, Masakatsu Sone6, Taiji Matsusaka7, Kazuwa Nakao8, Masashi Mukoyama1,5, 
Motoko Yanagita1 & Hideki Yokoi1
Connective tissue growth factor (CTGF) coordinates the signaling of growth factors and promotes 
fibrosis. Neonatal death of systemic CTGF knockout (KO) mice has hampered analysis of CTGF in adult 
renal diseases. We established 3 types of CTGF conditional KO (cKO) mice to investigate a role and 
source of CTGF in anti-glomerular basement membrane (GBM) glomerulonephritis. Tamoxifen-inducible 
systemic CTGF (Rosa-CTGF) cKO mice exhibited reduced proteinuria with ameliorated crescent 
formation and mesangial expansion in anti-GBM nephritis after induction. Although CTGF is expressed 
by podocytes at basal levels, podocyte-specific CTGF (pod-CTGF) cKO mice showed no improvement in 
renal injury. In contrast, PDGFRα promoter-driven CTGF (Pdgfra-CTGF) cKO mice, which predominantly 
lack CTGF expression by mesangial cells, exhibited reduced proteinuria with ameliorated histological 
changes. Glomerular macrophage accumulation, expression of Adgre1 and Ccl2, and ratio of M1/M2 
macrophages were all reduced both in Rosa-CTGF cKO and Pdgfra-CTGF cKO mice, but not in pod-
CTGF cKO mice. TGF-β1-stimulated Ccl2 upregulation in mesangial cells and macrophage adhesion to 
activated mesangial cells were decreased by reduction of CTGF. These results reveal a novel mechanism 
of macrophage migration into glomeruli with nephritis mediated by CTGF derived from mesangial cells, 
implicating the therapeutic potential of CTGF inhibition in glomerulonephritis.
Anti-glomerular basement membrane glomerulonephritis (anti-GBM nephritis) is a life-threatening disease1,2. 
Monocyte chemoattractant protein-1 (MCP-1 or CCL2) and transforming growth factor-β (TGF-β ) are reported 
to be major mediators of progressive anti-GBM nephritis3–5. Connective tissue growth factor (CTGF, also known 
as CCN2) is a 36–38 kDa protein and has been shown to be a downstream mediator of the profibrotic property of 
TGF-β 6–8. CTGF exerts multiple physiological actions, including extracellular matrix (ECM) accumulation, cell 
proliferation, cell adhesion and migration7–12.
In the kidney, CTGF mRNA is weakly expressed by podocytes and parietal epithelial cells under normal 
conditions13. CTGF is upregulated in mesangial proliferative lesions and crescents in patients with crescentic 
glomerulonephritis13. Previously, we demonstrated that podocyte-specific CTGF overexpression in mice leads to 
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glomerular injury in a streptozotocin–induced model of diabetes14, and that knockdown of CTGF gene expres-
sion ameliorates tubulointerstitial fibrosis in obstructive nephropathy15, indicating that CTGF is a mediator of 
renal fibrosis in vivo.
However, identification of the specific glomerular cell types responsible for pathological CTGF expression 
has remained unanswered. In the present study, we generated tamoxifen-inducible CTGF conditional KO 
(Rosa-CTGF cKO) mice to investigate importance of CTGF in the progression of anti-GBM nephritis, since 
conventional systemic CTGF KO mice die shortly after birth because of respiratory failure caused by skeletal 
defects16. Furthermore, we generated podocyte-specific CTGF conditional KO (pod-CTGF cKO) mice. Thirdly, 
we also established PDGFRα promoter-driven CTGF conditional KO (Pdgfra-CTGF cKO) mice, which predom-
inantly lack CTGF expression in mesangial cells of the glomeruli, to investigate the cell type-specific contribution 
of CTGF in anti-GBM nephritis model.
Results
Generation of CTGF floxed mice. To inactivate the Ctgf gene, we generated mice harboring Ctgfflox 
(Ctgffl) allele, which allows deletion of the entire Ctgf coding sequences (Supplementary Fig. S1a). We crossed 
Ctgffl/fl mice with ROSA26-CreERT2 mice to generate tamoxifen-inducible systemic Ctgf conditional KO (Rosa-
CTGF cKO) mice. Southern blot analysis showed efficient deletion of Ctgf gene in the kidney of male ROSA26-
CreERT2; Ctgf fl/fl mice treated with 4-hydroxytamoxifen (4-OHT, 0.05 mg/kgBW, three times) when they were 
3 weeks of age (Supplementary Fig. S1b). Gene expression of Ctgf in the kidneys of Rosa-CTGF cKO mice was 
decreased by 80% (Supplementary Fig. S1c) and Ctgf expression was also reduced in the heart, liver, and lungs 
(Supplementary Fig. S1d). Rosa-CTGF cKO mice exhibited healthy gross appearance with normal histology of 
the kidney, heart, liver, and lung (Supplementary Fig. S1e).
Rosa-CTGF cKO mice exhibited reduced proteinuria in anti-GBM nephritis model. To examine 
a role of CTGF in glomerulonephritis, we induced anti-GBM nephritis in Rosa-CTGF cKO and control mice. At 
8 weeks of age, 4-OHT-pretreated mutant and control mice were administered with anti-GBM serum (Fig. 1a), 
and renal examination was conducted 4 weeks later. CTGF was expressed weakly by podocytes and mesangial 
cells in normal glomeruli (Fig. 1b, Supplementary Fig. S2), and its expression was almost same as Rosa-CTGF 
cKO mice without nephritis (vehicle). Induction of anti-GBM nephritis resulted in increase of CTGF protein 
expression predominantly in the glomeruli, with a degree of co-localization with podocin, a podocyte marker 
(Fig. 1b, Supplementary Fig. S2). On the other hand, Rosa-CTGF cKO mice with anti-GBM nephritis exhibited a 
decrease in CTGF expression by podocytes and mesangial cells (Fig. 1b, Supplementary Fig. S2). No difference in 
urinary protein was observed between the vehicle-treated control and Rosa-CTGF cKO mice (Fig. 1c). Control 
mice with anti-GBM nephritis developed massive proteinuria that peaked at 1 week and decreased gradually 
thereafter (Fig. 1c). In contrast, Rosa-CTGF cKO mice with anti-GBM nephritis exhibited significantly reduced 
proteinuria at 1 week (Fig. 1c).
Microscopic examination indicated increased crescent formation and mesangial expansion in control mice 
with glomerulonephritis at 4 weeks (Fig. 1d). These changes were significantly ameliorated in Rosa-CTGF 
cKO mice with nephritis (Fig. 1d). Both control and Rosa-CTGF cKO mice with nephritis showed slight 
fibrotic changes in interstitial areas (Supplementary Fig. S3). Electron microscopic analysis demonstrated that 
Rosa-CTGF cKO mice without nephritis exhibited almost normal glomerular structure (Fig. 1f). Control mice 
with nephritis exhibited dense deposit accumulation along the GBM, and deposition was significantly reduced in 
Rosa-CTGF cKO mice with nephritis (Fig. 1f). Both Rosa-CTGF cKO mice and control mice showed liner rabbit 
and mouse IgG and C3 deposition along the GBM (Fig. 1g). These findings indicate that the deletion of CTGF 
did not affect the process of heterologous antibody-complement deposition or autologous antibody production.
Serum creatinine and blood urea nitrogen (BUN) levels were not different between control and Rosa-CTGF 
cKO mice with nephritis (Fig. 2a). Glomerular Ctgf mRNA expression in control mice with anti-GBM nephritis 
was 11 times higher than in control mice without nephritis (Fig. 2b). Glomerular Ctgf expression decreased by 
80% in Rosa-CTGF cKO mice with nephritis. Glomerular gene expression of Tgfb1, α -smooth muscle actin 
(Acta2), fibronectin (Fn1) and integrin α v (Itgav) was increased in control mice with nephritis and this increase 
was reduced in Rosa-CTGF cKO mice with nephritis (Fig. 2b,c). Glomerular CTGF protein of Rosa-CTGF cKO 
mice in GBM nephritis was also reduced compared with that of control mice (Fig. 2d). These results demonstrate 
that systemic deletion of CTGF ameliorates proteinuria and glomerular injury in anti-GBM nephritis.
Podocyte-specific inhibition of CTGF did not affect glomerulonephritis. To examine the contribu-
tion of glomerular cell types as sources of CTGF, we focused on podocytes because CTGF is expressed by podo-
cytes at basal levels. We generated podocyte-specific CTGF cKO (pod-CTGF cKO) mice and induced anti-GBM 
nephritis (Fig. 3a). Pod-CTGF cKO mice with anti-GBM nephritis exhibited a decrease in CTGF expression by 
podocytes (Fig. 3b). No difference in urinary protein excretion was observed between vehicle-treated control 
and pod-CTGF cKO mice (Fig. 3c). In glomerulonephritis, pod-CTGF cKO mice did not show improvements in 
proteinuria (Fig. 3c). Histological changes with nephritis, including crescent formation and mesangial expansion, 
in pod-CTGF cKO mice were not significantly different from control mice with nephritis (Fig. 3d,e). Electron 
microscopic analysis showed normal glomerular structure, including podocyte morphology, in pod-CTGF cKO 
mice without nephritis (Fig. 3f). Both control and pod-CTGF cKO mice with nephritis showed similar dense 
deposit accumulation along the GBM (Fig. 3f), with no significant difference of serum creatinine and BUN levels 
(Fig. 3g).
In control mice with nephritis, Ctgf, Tgfb1, Acta2, Fn1, and Itgav mRNA expressions in the glomeruli were 
increased compared with control mice without nephritis (Fig. 3h,i). Glomerular Ctgf expression decreased by 
50% in pod-CTGF cKO mice with nephritis compared with control mice with nephritis. No significant difference 
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Figure 1. Deletion of CTGF ameliorated proteinuria and histological changes in anti-GBM nephritis.  
(a) An experimental protocol for the study on the anti-GBM nephritis in tamoxifen-inducible systemic CTGF 
cKO (Rosa-CTGF cKO) mice. Three-week old male ROSA26-CreERT2; Ctgf fl/fl mice or control [Cre (− ); Ctgffl/fl]  
were intraperitoneally injected with 4-OHT, and anti-GBM nephritis was induced at 8 weeks of age (GBM). 
Vehicle treatment was also carried out in some animals (veh.). Mice were killed at 4 weeks after induction of anti-
GBM nephritis. (b) Double immunofluorescence staining for CTGF (green) and podocin (red) in the glomeruli  
of control or Rosa-CTGF cKO mice at 4 weeks after induction of anti-GBM nephritis. Bar represents 50 μ m.  
(c) Changes in proteinuria during the course of anti-GBM nephritis. Closed squares, vehicle-treated control mice; 
open square, vehicle-treated Rosa-CTGF cKO mice; closed circles, control mice with GBM nephritis; open circles, 
Rosa-CTGF cKO mice with anti-GBM nephritis. (d) Representative photomicrographs of the kidneys at 4 weeks 
after induction of anti-GBM nephritis (PAS staining). Left upper panel, vehicle-treated control mice; right upper 
panel, vehicle-treated Rosa-CTGF cKO mice; left lower panel, control mice with anti-GBM nephritis; right lower 
panel show, Rosa-CTGF cKO mice with anti-GBM nephritis. Bar represents 50 μ m. (e) The percentage of crescent 
formation (left panel) and the mesangial area (right panel) in anti-GBM nephritis. (f) Electron microscopic 
analysis of glomeruli. Bar represents 2,000 nm. (g) Immunofluorescence studies for rabbit IgG, mouse IgG and 
mouse C3 deposition in the kidney at 28 days after induction of anti-GBM nephritis in control and in Rosa-CTGF 
cKO mice. Both Rosa-CTGF cKO and control mice exhibited liner IgG and C3 deposition along the GBM. Bar 
represents 50 μ m. Values are expressed as means ± s.e. *P < 0.05, **P < 0.01 vs control mice with GBM nephritis. 
Vehicle-treated control mice (n = 7), vehicle-treated Rosa-CTGF cKO mice (n = 7), control mice with GBM 
nephritis (n = 7), Rosa-CTGF mice with GBM nephritis (n = 9). Veh, vehicle; GBM, anti-GBM nephritis.
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in the expression of other mRNA transcripts was observed between control and pod-CTGF cKO mice with 
nephritis (Fig. 3h,i). Glomerular CTGF protein was also reduced in pod-CTGF cKO mice with nephritis (Fig. 3j). 
These results indicate that podocyte-specific inhibition of CTGF does not ameliorate proteinuria and glomerular 
injury in anti-GBM nephritis.
Reduction of CTGF in mesangial cells ameliorated glomerulonephritis. Next, we focused on 
mesangial cells and generated Pdgfra-CTGF cKO mice to eliminate CTGF in mesangial cells. PDGFRα was pre-
dominantly expressed by mesangial cells in normal glomeruli, and its expression was increased after induction of 
anti-GBM nephritis (Supplementary Fig. S4a). Pdgfra-ZsGreen mice showed that ZsGreen was localized in cells 
positive for PDGFRβ , a representative mesangial and fibroblast marker, and was not co-localized with podocin 
or an endothelial marker PECAM1 (Supplementary Fig. S4b,c), and that ZsGreen was partly co-localized with 
cells positive for Megalin (Supplementary Fig. S4d), a proximal tubular cell marker, and aquaporin 2 (AQP2), a 
collecting duct cell marker (Supplementary Fig. S4e). These results indicate that PDGFRα was predominantly 
expressed by mesangial cells within glomeruli in anti-GBM nephritis. Pdgfra-ZsGreen mice in control exhibited a 
few ZsGreen-positive cells in bone marrow (Supplementary Fig. S5a). These ZsGreen-positive cells sorted by flow 
cytometry expressed little Ctgf mRNA (Supplementary Fig. S5b), suggesting that Pdgfra-CTGF cKO mice do not 
have any changes in Ctgf mRNA expression in bone marrow cells compared with control mice.
To examine a role of CTGF expressed by mesangial cells in anti-GBM nephritis, we induced anti-GBM nephri-
tis in Pdgfra-CTGF cKO mice (Fig. 4a). CTGF was expressed by cells other than podocytes, presumably mesan-
gial cells, in nephritis (Fig. 4b). Pdgfra-CTGF cKO mice with nephritis showed reduction of CTGF expression in 
mesangial cells (Fig. 4b) and proteinuria at 1 and 4 weeks (Fig. 4c)
Crescent formation was significantly reduced in Pdgfra-CTGF cKO mice with nephritis and mesangial expan-
sion tended to be decreased in Pdgfra-CTGF cKO mice with nephritis compared with control mice with nephritis 
Figure 2. Systemic deletion of CTGF reduced mRNA expression of fibrotic makers in anti-GBM nephritis. 
(a) Serum creatinine and BUN levels. No significant difference between control and Rosa-CTGF cKO mice 
with nephritis. (b) Expression of Ctgf and Tgfb1 mRNA in the glomeruli of the kidney at 4 weeks after 
induction of anti-GBM nephritis. Glomerular Ctgf expression decreased by 80% in Rosa-CTGF cKO mice 
with nephritis compared with control mice with nephritis. Tgfb1 expression was also decreased in Rosa-CTGF 
cKO with nephritis. (c) Expression of Acta2, Fn1 and Itgav mRNA in the glomeruli. Gapdh mRNA expression 
was used as internal control. (d) Glomerular CTGF protein at 4 weeks after induction of anti-GBM nephritis 
by Western blotting (n = 4, each). β -actin was used as internal control. Full-length blots are presented in 
Supplementary Figure S10. Values are expressed as means ± s.e. *P < 0.05, **P < 0.01. Vehicle-treated control 
mice (n = 7), vehicle-treated Rosa-CTGF cKO mice (n = 7), control mice with anti-GBM nephritis (n = 7), 
Rosa-CTGF cKO mice with anti-GBM nephritis (n = 9). Veh, vehicle; GBM, anti-GBM nephritis.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:42114 | DOI: 10.1038/srep42114
Figure 3. Podocyte-specific inhibition of CTGF did not ameliorate glomerular changes. (a) Experimental 
protocol for anti-GBM nephritis in podocyte-specific CTGF cKO mice (pod-CTGF cKO). (b) Double 
immunofluorescence staining for CTGF (green) and podocin (red) in glomeruli of pod-CTGF cKO mice at 4 
weeks after induction of anti-GBM nephritis. Pod-CTGF cKO mice with anti-GBM nephritis exhibited a decrease 
in CTGF expression by podocytes. Lower panel, pod-CTGF cKO mice with anti-GBM nephritis. Bar represents 
50 μ m. (c) Changes in proteinuria during the course of the anti-GBM nephritis. Closed squares, vehicle-treated 
control mice; open squares, pod-CTGF cKO mice with vehicle; closed circles, control mice with anti-GBM 
nephritis; open circles, pod-CTGF cKO mice with anti-GBM nephritis. (d) Representative photomicrographs 
of the kidneys at 4 weeks after induction of anti-GBM nephritis (PAS staining). Left upper panel, vehicle-treated 
control mice; right upper panel, vehicle-treated pod-CTGF cKO mice; left lower panel, control mice with anti-
GBM nephritis; right lower panel, pod-CTGF cKO mice with anti-GBM nephritis. Bar represents 50 μ m.  
(e) The percentage of crescent formation (left panel) and the mesangial area (right panel) in anti-GBM nephritis 
in pod-CTGF cKO mice. (f) Electron microscopic analysis of glomeruli in anti-GBM nephritis in pod-CTGF 
cKO mice. No difference in dense deposit accumulation (white arrows) between control and pod-CTGF cKO 
mice with nephritis. Bar represents 2,000 nm. (g) Serum creatinine and BUN levels in pod-CTGF cKO mice with 
anti-GBM nephritis. (h) Expression of Ctgf and Tgfb1 mRNA in glomeruli at 4 weeks after induction of anti-
GBM nephritis. (i) Expression of Acta2, Fn1and Itgav mRNA in glomeruli. (j) Representative image of glomerular 
CTGF protein by Western blotting. Immunoblot of β -actin was used as control. Full-lengh blots are presented in 
Supplementary Figure S11. Values are expressed as means ± s.e. *P < 0.05, **P < 0.01. Vehicle-treated control mice 
(n = 9), vehicle-treated pod-CTGF cKO mice (n = 6), control mice with anti-GBM nephritis (n = 7), pod-CTGF 
mice with anti-GBM nephritis (n = 7). Veh, vehicle; GBM, anti-GBM nephritis.
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Figure 4. Reduction of CTGF in mesangial cell ameliorated glomerulonephritis. (a) Experimental protocol 
anti-GBM nephritis in Pdgfra-CTGF cKO mice. Anti-GBM nephritis was induced at 8 weeks of age. Mice were 
killed at 4 weeks after induction of anti-GBM nephritis. (b) Double immunofluorescence staining for CTGF (green) 
and podocin (red) in the glomeruli of Pdgfra-CTGF cKO or control mice at 4 weeks after induction of anti-GBM 
nephritis. Bar represents 50 μ m. (c) Changes in proteinuria during the course of the anti-GBM nephritis. Closed 
squares, vehicle-treated control mice; open squares, vehicle-treated Pdgfra-CTGF cKO mice; closed circles, control 
mice with nephritis; open circles, Pdgfra-CTGF cKO mice with nephritis. (d) Representative photomicrographs 
of the kidneys at 4 weeks after induction of anti-GBM nephritis (PAS staining). Left upper panel, vehicle-treated 
control mice; right upper panel, vehicle-treated Pdgfra-CTGF cKO mice; left lower panel, control mice with  
anti-GBM nephritis; right lower panel, Pdgfra-CTGF cKO mice with anti-GBM nephritis. Bar represents 50 μ m. 
(e) The percentage of crescent formation (left panel) and the mesangial area (right panel) in anti-GBM nephritis. 
(f) Electron microscopic analysis of glomeruli in anti-GBM nephritis in Pdgfra-CTGF cKO mice. Dense deposit 
accumulation along GBM was reduced in Pdgfra-CTGF cKO mice with nephritis (white arrows). Bar represents 
2,000 nm. (g) Serum creatinine and BUN levels in anti-GBM nephritis in Pdgfra-CTGF cKO mice. (h) Expression 
of Ctgf and Tgfb1 mRNA in glomeruli at 4 weeks after induction of anti-GBM nephritis. (i) Expression of Acta2, 
Fn1 and Itgav mRNA in glomeruli. (j) Representative image of glomerular CTGF protein by Western blotting. 
Immunoblot of β -actin was used as control. Full-length blots are presented in Supplementary Figure S12. Values 
were expressed as means ± s.e. *P < 0.05, **P < 0.01 vs control mice with anti-GBM nephritis. Vehicle-treated 
control mice (n = 6), vehicle-treated Pdgfra-CTGF cKO mice (n = 6), control mice with anti-GBM nephritis (n = 9), 
Pdgfra-CTGF cKO mice with anti-GBM nephritis (n = 6). Veh, vehicle; GBM, anti-GBM nephritis.
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(Fig. 4d,e). Electron microscopic analysis revealed a reduction in dense deposit accumulation along the GBM 
in Pdgfra-CTGF cKO mice with nephritis (Fig. 4f). Pdgfra-CTGF cKO mice exhibited a reduction in the serum 
creatinine level, but not in BUN levels compared with control mice with nephritis (Fig. 4g). Glomerular Ctgf 
expression was decreased by 60% in Pdgfra-CTGF cKO mice with nephritis compared with control mice with 
nephritis (Fig. 4h). Tgfb1, Acta2, Fn1 and Itgav mRNA expression in the glomeruli was increased in control mice 
with nephritis, and this increase was reduced in Pdgfra-CTGF cKO mice with nephritis (Fig. 4h,i). These results 
indicate that deletion of mesangial cell-derived CTGF ameliorates glomerular injury in anti-GBM nephritis.
Role of macrophages in anti-GBM nephritis. We evaluated glomerular MAC-2-positive macrophages in 
each CTGF cKO mouse line because macrophages have been shown to aggravate anti-GBM nephritis17–19. Mac-2, 
also known as galectin-3, is positive for macrophages and distal tubular cells in the kidney20,21, thus positive cells 
within glomerular area indicate macrophages. Control mice with nephritis showed an increase in MAC-2-positive 
cells (Fig. 5a). Rosa-CTGF cKO mice with nephritis exhibited significantly less accumulation of glomerular MAC-
2-positive cells (Fig. 5a). In contrast, pod-CTGF cKO mice with nephritis showed no decrease in the number of 
MAC-2-positive cells in glomeruli (Fig. 5b). Accumulation of MAC-2-positive cells in Pdgfra-CTGF cKO mice 
with nephritis was significantly milder than that in control mice with nephritis (Fig. 5c), indicating that mesangial 
cells play an important role in macrophage infiltration. Gene expression of a macrophage marker F4/80 (Adgre1) 
and CCL2, which has a potent activity to regulate migration and infiltration of macrophages22, showed similar 
results (Fig. 5d–i). To study M1 and M2 macrophage subtypes (or polarity) in glomeruli with and without anti-GBM 
nephritis, the ratio of CD11c (Itgax, M1 marker) and CD206 (Mrc1, M2 marker) was examined (Fig. 6a–f). The M1/
M2 ratio in control mice with anti-GBM nephritis was higher than control mice without nephritis. M1/M2 ratios 
were significantly lower in Rosa-CTGF cKO and Pdgfra-CTGF cKO mice with nephritis compared with those in 
control mice with nephritis, but not in pod-CTGF cKO mice with nephritis (Fig. 6g–i).
Macrophage recruitment in Rosa-CTGF cKO mice with anti-GBM nephritis at the earlier 
stage. We examined the effects of CTGF deletion at the earlier stage, 1 week. Rosa-CTGF cKO mice or con-
trol mice were administered with anti-GBM serum (Supplementary Fig. 6a), and renal examination was con-
ducted at 1 week later. Induction of anti-GBM nephritis resulted in increase of CTGF protein expression at 1 
week predominantly in the glomeruli, and Rosa-CTGF cKO mice with anti-GBM nephritis exhibited a decrease 
in CTGF expression by podocytes and mesangial cells (Supplementary Fig. 6b). Rosa-CTGF cKO mice with 
anti-GBM nephritis exhibited significantly reduced proteinuria at 1 week compared with control mice with 
nephritis (Supplementary Fig. 6c; P < 0.05). Microscopic examination indicated increased crescent formation 
and mesangial expansion were significantly ameliorated in Rosa-CTGF cKO mice with nephritis as follows 
(Supplementary Fig. 6d,e). The number of macrophages in glomeruli was evaluated by immunohistochemistry 
for MAC-2 (Supplementary Fig. 6f). Rosa-CTGF cKO mice with nephritis exhibited significantly less accumu-
lation of glomerular MAC-2-positive cells compared with control mice with nephritis (Supplementary Fig. 6g). 
Serum creatinine levels were elevated in control mice with nephritis; however, no significant difference was 
observed between control and Rosa-CTGF cKO mice with nephritis (Supplementary Fig. 6h). Electron micro-
scopic analysis demonstrated both control and Rosa-CTGF cKO mice with nephritis demonstrated slight dense 
deposit accumulation (Supplementary Fig. S7a).
Glomerular Ctgf expression decreased in Rosa-CTGF cKO mice with nephritis compared with control mice 
with nephritis (Supplementary Fig. S7b). Glomerular gene expression of integrin α v (Itgav) mRNA expression 
was increased in control mice with nephritis and this increase was reduced in Rosa-CTGF cKO mice with nephri-
tis at 1 week (Supplementary Fig. S7c). Expression of Fn1, Acta2, Tgfb1, Adgre1 or Ccl2 was tended to be reduced 
in Rosa-CTGF cKO mice with nephritis, but not significant (Supplementary Fig. S7d–h). We also examined 
M1 and M2 macrophage subtypes at 1 week in glomeruli with and without anti-nephritis. Expression of both 
CD11c (Itgax) and CD206 (Mrc1) was increased in control mice with nephritis, and their expression was sig-
nificantly reduced in Rosa CTGF cKO mice with nephritis (Supplementary Fig. S7i,j). When M1/M2 ratio was 
examined, no significant difference was observed among control and Rosa-CTGF cKO with nephritis at 1 week 
(Supplementary Fig. S7k). These results suggest that systemic deletion of CTGF ameliorates proteinuria and glo-
merular injury by reducing macrophage recruitment at 1 week after induction of anti-GBM nephritis.
Effects of CTGF inhibition in cultured mesangial cells and macrophages. Next, we focused on 
the effect of CTGF on inflammation and macrophage subtypes in vitro. We examined whether TNF-α induced 
macrophage subtype. Stimulation with TNF-α increased both Itgax and Mrc1 mRNA in cultured macrophages 
(Fig. 7a,b), leading to the increment of M1/M2 ratio (Fig. 7c). Next, we examined the effects of CTGF on mac-
rophage subtypes. Although expression of Itgax was not altered by the stimulation of CTGF (Fig. 7d), expres-
sion of Mrc1 was significantly decreased with CTGF in cultured macrophages (Fig. 7e). Consequently, the M1/
M2 ratio was significantly upregulated with the stimulation of recombinant CTGF (Fig. 7f). In addition, CTGF 
induced Tnfa mRNA in cultured macrophages (Fig. 7g).
To examine the effect of CTGF on migration, we first investigated the expression of Ccl2 following treatment 
with CTGF and/or TGF-β 1 in cultured mesangial cells, because CCL2 is a major mediator of macrophage recruit-
ment. CTGF and TGF-β 1 upregulated Ccl2 mRNA expression, and the combination of CTGF and TGF-β 1 further 
enhanced Ccl2 expression in cultured mesangial cells (Fig. 8a). The expression of Ccl2 was reduced by CTGF 
inhibition in TGF-β 1-treated mesangial cells (Fig. 8b). Treatment with recombinant human CTGF overcame the 
effects of endogenous CTGF inhibition in TGF-β 1-induced CCl2 mRNA upregulation (Fig. 8c). Inhibition of 
CTGF by si-CTGF was confirmed by Western blotting (Fig. 8d). These results suggest that CTGF upregulation in 
mesangial cells plays an important role in regulating Ccl2 expression.
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We further investigated the effects of CTGF on adhesion of macrophages to activated mesangial cells (Fig. 8e). 
Fluorescein-dye-labeled RAW264.7 cells were co-cultured with recombinant TNF-α -stimulated mesangial 
cells on culture plates (Fig. 8f,g). The increase in macrophage adhesion by TNF-α stimulation was significantly 
Figure 5. Role of CTGF on macrophage accumulation in anti-GBM nephritis. (a–c) Immunohistochemical 
studies for MAC-2 to analyze the number of MAC-2-positive cells per a glomerulus of Rosa-CTGF cKO mice 
(a), pod-CTGF cKO mice (b) and Pdgfra-CTGF cKO mice (c) at 4 weeks after induction of anti-GBM nephritis. 
Bar represents 50 μ m. (d–f) Expression of Adgre1 (F4/80) mRNA in the glomeruli of Rosa-CTGF cKO mice 
(d), pod-CTGF cKO mice (e) and Pdgfra-CTGF cKO mice (f) at 4 weeks after induction of anti-GBM nephritis. 
(g–i) Ccl2 mRNA expression in glomeruli of Rosa-CTGF cKO mice (g), pod-CTGF cKO mice (h) and Pdgfra-
CTGF cKO mice (i) at 4 weeks after induction of anti-GBM nephritis. Veh., vehicle; GBM, anti-GBM nephritis; 
Rosa cKO, Rosa-CTGF cKO mice; pod cKO, pod-CTGF cKO mice; Pdgfra cKO, Pdgfra-CTGF cKO mice. 
Values were expressed as the means ± s.e. *P < 0.05, **P < 0.01.
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inhibited by CTGF knockdown in mesangial cells, and this reduction was canceled by exogenous CTGF adminis-
tration (Fig. 8f,g). We next examined the mRNA expression of adhesion molecules in cultured mesangial cells rel-
evant to macrophage adhesion. The expression of Icam1 and Vcam1 did not change following CTGF knockdown 
but was increased by TNF-α stimulation (Fig. 8h–j). In contrast, the expression of Fn1 and Itgav was significantly 
reduced by CTGF knockdown; however this reduction was not affected by TNF-α (Fig. 8k,l), raising a possibility 
that CTGF may enhance macrophage adhesion to mesangial cells through expression of fibronectin and integrin 
α v. We next examined the role of CTGF on macrophage adhesion to endothelial cells (Supplementary Fig. S8a). 
The increase of macrophage adhesion to TNF-α -stimulated HUVEC was significantly attenuated by CTGF reduc-
tion (Supplementary Fig. S8b,c), indicating that CTGF is involved in macrophage adhesion to endothelial cells.
Figure 6. Relevance of CTGF to macrophage phenotypes in anti-GBM nephritis. (a–c) Expression of Itgax 
(CD11c, M1 marker) mRNA in the glomeruli of Rosa-CTGF cKO mice (a), pod-CTGF cKO mice (b) and 
Pdgfra-CTGF cKO mice (c) at 4 weeks after induction of anti-GBM nephritis. (d–f) Mrc1 (CD206, M2 marker) 
mRNA expression in the glomeruli of Rosa-CTGF cKO mice (d), pod-CTGF cKO mice (e) and Pdgfra-CTGF 
cKO mice (f). (g–i) Ratio of mRNA expression of M1/M2 macrophage markers in the glomeruli of Rosa-
CTGF cKO mice (g), pod-CTGF cKO mice (h) and Pdgfra-CTGF cKO mice (i).Veh, vehicle; GBM, anti-GBM 
nephritis; Rosa cKO, Rosa-CTGF cKO mice; pod cKO, pod-CTGF cKO mice; Pdgfra cKO, Pdgfra-CTGF cKO 
mice. Values were expressed as the means ± s.e. *P < 0.05, **P < 0.01.
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Discussion
In the present study, we investigated a role of CTGF in a mouse model of anti-GBM nephritis, using three types of 
conditional CTGF KO mice. Although a previous study showed that inducible systemic CTGF KO mice lacking 
exon 4 grow normally23, the present study is the first to describe a role of CTGF in kidney diseases using systemic 
conditional KO mice. Our work revealed that renal injury induced by anti-GBM nephritis is markedly inhib-
ited in inducible systemic CTGF KO mice lacking the whole CTGF coding region. Blockade of CTGF has been 
shown to exert renoprotective effects in a number of renal diseases, including diabetic nephropathy and unilateral 
Figure 7. The effects of CTGF on macrophage subtypes. (a,b) Expression of Itgax (a) and Mrc1 (b) by  
10 ng/ml TNF-α in RAW264.7 cells at 3 h after stimulation. (c) Ratio of mRNA expression of M1/M2 
macrophage markers in RAW264.7 cells after stimulation with TNF-α . (d,e) Expression of Itgax (d) and Mrc1 
(e) by 1000 ng/ml CTGF in RAW264.7 cells. (f) Ratio of mRNA expression of M1/M2 macrophage markers in 
RAW264.7 cells after stimulation with 1000 ng/ml CTGF. (g) Induction of Tnfa expression by treatment with 
1000 ng/ml CTGF in RAW264.7 cells. hCTGF, recombinant human CTGF. n = 6, each. Values were expressed as 
the means ± s.e. *P < 0.05, **P < 0.01.
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Figure 8. The effects of CTGF on chemotasis in cultured mesangial cells and adhesion of cultured 
macrophage to activated mesangial cells. (a) Induction of Ccl2 expression by treatment with 500 ng/ml 
CTGF and/or 1 ng/ml TGF-β 1 in cultured mesangial cells. (b) Reduction of Ccl2 expression by CTGF siRNA 
in cultured mesangial cells. (c) Amelioration of siRNA-mediated Ccl2 reduction by treatment of exogenous 
CTGF (100 ng/ml). hCTGF, recombinant human CTGF; siCTGF, siRNA against CTGF. (d) Immunoblt of 
CTGF by CTGF siRNA in cultured mesangial cells by Western blotting. Full-length blots are presented in 
Supplementary Figure S13. (e–g) Macrophage adhesion to cultured mesangial cells on culture plates.  
(e) Experimental protocol of adhesion of fluorescein-dye-labeled RAW264.7 cells to 10 ng/ml TNF-α 
-stimulated mesangial cells. (f) Inhibition of CTGF by siRNA reduced macrophage adhesion, and this reduction 
was ameliorated by exogenous human CTGF (100 ng/ml). Bar represents 100 μ m. (g) Quantitative analyses of 
adhesion of RAW264.7 cells to cultured mesangial cells. (h) Ctgf mRNA expression in cultured mesangial cells 
with the stimulation of 10 ng/ml TNF-α . (i–l) Expression of Icam1 (i), Vcam1 (j), Fn1 (k) and Itgav (l) mRNA in 
mesangial cells after stimulation of 10 ng/ml TNF-α . n = 6, each. *P < 0.05, **P < 0.01.
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ureteral obstruction15,24. This study clearly showed that inhibition of CTGF can ameliorate immune-complex 
mediated glomerulonephritis. We demonstrated the reduction of urinary protein, crescentic formation, mesan-
gial expansion and electron dense deposits without changing heterologous, autologous antibodies or C3 com-
plement deposition. The previous reports showed that discrepancy between IgG deposition and electron dense 
deposits in anti-GBM nephritis was documented25,26, which were consistent with our results.
Although we demonstrated the importance of CTGF on anti-GBM nephritis, identification of the specific glo-
merular cell types responsible for pathological CTGF expression has remained unanswered. To address this issue, 
we employed other conditional KO mice in anti-GBM nephritis. Previous reports revealed that podocytes are the 
cells most severely affected by anti-GBM nephritis27, demonstrating the importance of podocytes in this model. 
In this context, we investigated whether CTGF reduction in podocytes could ameliorate anti-GBM nephritis 
using pod-CTGF cKO mice, because CTGF has been shown to be upregulated by podocytes and mesangial cells 
in crescentic glomerulonephritis in both humans and rats13,28. In crescentic glomerulonephritis, podocytes are 
considered to contribute to crescent formation and proteinuria29. Surprisingly, the present study demonstrated 
that pod-CTGF cKO mice with anti-GBM nephritis showed no improvement in proteinuria or histological 
changes. These results prove that abundant CTGF expression in podocytes does not play a major role in glomer-
ular injury of anti-GBM nephritis.
Concerning the glomerular cell types that contribute to CTGF actions in nephritis, we next focused on 
mesangial cells. However, there are no known mice strains that specifically express Cre in mesangial cells30. 
Therefore, we focused on PDGFRα , which is weakly expressed predominantly in mesangial cells under normal 
conditions and more strongly in glomerulonephritis31,32. We confirmed that PDGFRα was expressed in mesan-
gial regions in mice with anti-GBM nephritis (Supplementary Fig. S4b), and confirmed minor contribution of 
bone marrow-derived cells (Supplementary Fig. S5). Notably, Pdgfra-CTGF cKO mice with anti-GBM nephritis 
exhibited significantly reduced proteinuria and decreased crescent formation and mesangial expansion, similar 
to findings observed in Rosa-CTGF cKO mice. Of note, the creatinine levels only in Pdgfra-CTGF cKO mice 
with anti-GBM nephritis was reduced compared with that in control mice with nephritis, although Rosa-CTGF 
cKO with nephritis mice did not show the decreased creatinine level. These results may be due to incomplete 
deletion of CTGF alleles in Pdgfra-positive cells of Rosa-CTGF cKO mice. Although we and others have shown 
that PDGFRα is also expressed in the collecting ducts, proximal tubular cells and interstitial fibroblasts of the 
kidney33, glomerular mesangial cells expressing both PDGFRα and CTGF appear to make predominant contri-
bution to glomerular injury in anti-GBM nephritis. It is a limitation of this study that Pdgfra-Cre mice express 
Cre recombinase not only in mesangial cells but also in other type cells.
CTGF has been reported to be a crucial mediator of organ fibrosis and proinflammatory responses. CTGF has 
been also shown to upregulate chemokines and adhesion molecules to promote cell migration and adhesion34–37. 
In the present study, accumulation of MAC-2-positive cells in the glomeruli was decreased in Rosa-CTGF cKO 
and Pdgfra-CTGF cKO mice at 4weeks, but not in pod-CTGF cKO mice. The glomerular Ccl2 and Adgre1 expres-
sion and the M1/M2 macrophage marker ratio were decreased in Rosa-CTGF cKO and Pdgfra-CTGF cKO 
mice, indicating that CTGF expression particularly in mesangial cells is critical to induction of inflammation in 
anti-GBM nephritis. Sánchez-López et al. demonstrated that systemic administration of full length or C-terminal 
module 4 of CTGF to mice increase renal expression of Ccl2, leading to recruitment of immune cells35,38. Several 
studies have reported that the inhibition of macrophage infiltration ameliorates anti-GBM nephritis17–19. We 
examined the renal changes at 1 week after induction of nephritis using Rosa-CTGF cKO mice, indicating that 
CTGF deletion resulted in reduced accumulation of macrophages. Recently, CTGF has been shown to be involved 
with increase of M1 and decrease of M2 macrophages in pancreatic β -cell ablation model39. Our study reveals 
that ablation of CTGF did not reduce M1/M2 ratio at 1 week but at 4 weeks in vivo and that recombinant CTGF 
increased M1/M2 ratio in vitro. Further studies are necessary to elucidate the mechanism of macrophage subtype 
transition by CTGF at each time point. We investigated the effects of CTGF reduction on inflammation in cul-
tured mesangial cells in vitro, demonstrating that mRNA expression of Ccl2 was increased by CTGF stimulation. 
TGF-β -induced Ccl2 expression was downregulated by CTGF inhibition and this downregulation was abrogated 
by exogenous CTGF. These data suggest that CTGF from mesangial cells, not podocytes, may be required for the 
upregulation of Ccl2 expression not only in anti-GBM nephritis but also in other types of glomerulonephritis 
such as IgA nephropathy or crescentic glomerulonephritis, because CTGF expression and accumulation of mac-
rophages in mesangial area are documented in these glomerular diseases.
The present study demonstrated that increased macrophage adhesion to mesangial cells in response to TNF-α 
was significantly reduced by CTGF knockdown using siRNA transfection. Although previous reports have 
demonstrated that CTGF enhances adhesion through interactions with integrins and fibronectin on endothelial 
cells and fibroblasts40,41, we demonstrate here the importance of mesangial cells in regulating macrophage adhe-
sion through CTGF-dependent expression of fibronectin and integrin α v during nephritis. As previous reports 
showed that endothelial cells are involved in the macrophage chemotaxis and attachments, this study also eval-
uated the important role of CTGF on macrophage adhesion to endothelial cells. Further analysis will be neces-
sary to reveal a precise mechanism playing a role in macrophage adhesion on endothelial cells. These results of 
the present study suggest that CTGF induces macrophage accumulation in anti-GBM nephritis by enhancing 
both chemotaxis and adhesion, and that reduction of CTGF, particularly in mesangial cells, ameliorates nephritis 
via inhibition of macrophage infiltration (Supplementary Fig. S9). The present study unveils a novel crosstalk 
between mesangial cells and macrophages in the progression of glomerulonephritis42.
In conclusion, systemic reduction in CTGF expression can ameliorate proteinuria and glomerular 
injury in anti-GBM nephritis through suppression of inflammation and extracellular matrix accumulation. 
Furthermore, we observed a novel role of mesangial cells in enhancing macrophage chemotaxis and adhesion in 
a CTGF-dependent manner. These findings demonstrate the importance of CTGF in the progression of glomeru-
lonephritis and suggest that CTGF represents a promising therapeutic target for glomerulonephritis.
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Materials and Methods
Experimental animals. A BAC clone containing the complete mouse Ctgf gene was isolated from a mouse 
C57BL/6 J genomic library. A DNA fragment containing Ctgf gene was generated by PCR using the BAC clone 
and then inserted into the targeting vector. Two loxP sites were introduced into the targeting vector at 12 bp 
upstream of the ATG codon and immediately after the stop codon TAA by PCR based mutagenesis43. The target-
ing vector contained two flippase recombination target (FRT) sites that flank the neomycin resistant gene. The tar-
geting vector was designed to induce conditional deletion of exons 1–5 of the mouse Ctgf gene flanked with loxP 
sequences (Supplementary Fig. S1a). The final linearized vector was introduced into mouse C57BL/6 J embryonic 
stem (ES) cells and these cells were selected with Geneticin (G418, ThermoFisher Scientific, Waltham, MA) and 
Fialuridine (FIAU, Sigma Aldrich, St. Louis, MO). Positive clones were selected by Southern blotting and PCR 
analysis, injected into blastocysts, and brought to term in surrogate mothers. These animals were crossed with 
transgenic mice expressing flippase constitutively to remove the neomycin resistance gene.
C57BL/6-Gt (ROSA) 26Sortm9 (cre/ESR1) Art (ROSA26-CreERT2) mice44 were purchased from ARTEMIS 
Pharmaceuticals. C57BL/6-Tg(Pdgfra-Cre)1Clc/J mice (Pdgfra-Cre mice) and B6.Cg-Gt(ROSA)Sortm6(CAG-ZsGreen1)
Hze/J mice were purchased from the Jackson Laboratory. Nephrin-Cre mice were constructed as described previously45. 
Tamoxifen-inducible systemic CTGF conditional KO (Rosa-CTGF cKO) mice were generated by mating CTGFfl/fl  
mice and Rosa-CreERT2 mice. Three-week-old ROSA26-CreERT2; Ctgf fl/fl mice or control [CTGFfl/fl, Cre (− )] 
mice were intraperitoneally injected with 0.05 mg/gBW 4-hydroxytamoxifen (4-OHT, Sigma Aldrich) for 3 days. 
Pod-CTGF cKO and Pdgfra-CTGF cKO mice were generated by crossing CTGFfl/fl mice with Nephrin-Cre or 
Pdgfra-Cre mice, respectively. B6.Cg-Gt (ROSA) Sortm6 (CAG-ZsGreen1) Hze/J mice were crossed with Pdgfra-Cre mice 
to generate Pdgfra-ZsGreen mice. Mice were maintained in a specific pathogen-free facility. All animal experi-
ments were performed in accordance with Fundamental Guidelines for Proper Conduct of Animal Experiment 
and Related Activities in Academic Research Institutions and were approved by the Animal Experimentation 
Committee of Kyoto University Graduate School of Medicine.
Induction of anti-glomerular basement antibody nephritis. An accelerated form of anti-GBM 
nephritis was induced in Rosa-CTGF cKO, pod-CTGF cKO, Pdgfra-CTGF cKO, and Pdgfra-ZsGreen mice. 
Preparation of anti-GBM antiserum in rabbits was performed as described previously46. Mice were immunized 
by an intraperitoneal injection of 0.5 mg/20 gBW of normal rabbit IgG (MP Biomedicals, Santa Ana, CA) emul-
sified with complete Freund’s adjuvant (Difco, Detroit, MI) at 8 weeks of age, and anti-GBM antibody or vehicle 
(normal rabbit serum) was injected into the tail vein 5 days later. Urinary protein levels and body weights were 
measured on days 0, 3, 7, 14, and 28 after induction of anti-GBM nephritis. For urinary measurements, each ani-
mal was housed separately in a metabolic cage (Shinano Manufacturing, Tokyo, Japan). Urinary protein, urinary 
creatinine, serum creatinine and BUN were measured by enzymatic method (SRL, Tokyo, Japan). Mice were 
killed at 1 or 4 weeks after the induction of anti-GBM nephritis under pentobarbital anesthesia. Blood and kidney 
samples were collected for biochemical and histological analyses. Glomeruli were isolated by the graded sieving 
method as described previously43.
Renal histology and electron microscopy. Histological and electron microscopic examinations were 
performed as described previously14,47. Briefly, kidney sections stained with periodic acid-Schiff (PAS) and 
Masson’s trichrome (MT) were examined by light microscopy (IX-81, Olympus, Tokyo, Japan). The ratio of cres-
centic glomeruli to total glomeruli was calculated as the crescent formation ratio. Mesangial areas in 10 superficial 
glomeruli were measured quantitatively using computer-aided manipulator (MetaMorph software, Molecular 
Devices, Sunnyvale, CA) with mean values calculated. These procedures were performed by investigators blinded 
to the origin of the slides. Electron microscopic examination was performed in an electron microscope (H-7600, 
Hitachi, Tokyo, Japan).
Immunohistochemistry. Immunofluorescence and immunohistochemical studies of the kidney sam-
ples were performed as previously described47. Primary antibodies used were FITC-labeled donkey anti-rabbit 
IgG (Jackson ImmunoResearch, West Grove, PA), FITC-labeled anti-mouse IgG (Jackson ImmunoResearch), 
FITC-labeled goat anti-mouse C3 antibodies (MP Biomedicals), goat anti-CTGF antibody (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA), rabbit anti-podocin antibody (Sigma-Aldrich), rat anti-MAC-2 anti-
body (Cedarlane, Burlington, Ontario, Canada), rat anti-mouse PECAM1 antibody (BD Biosciences, San Jose, 
CA), rat anti-mouse PDGFRβ antibody (Biolegend, San Diego, CA), goat anti-Megalin antibody (Santa Cruz 
Biotechnology), and goat anti-AQP2 (Santa Cruz Biotechnology). Four-μ m-thick cryostat sections fixed in ace-
tone were incubated with primary antibodies and then examined by fluorescence microscopy. For double immu-
nofluorescence analysis of CTGF and podocin, the kidney sections were fixed using Dubosq-Brazil solution and 
embedded in paraffin. The sections were boiled for 10 min, followed by incubation with goat anti-CTGF antibody 
and Hylite Flour 555 (Dojindo, Tokyo, Japan)-labeled anti-podocin antibody for 1 hour. The sections were then 
incubated with FITC-donkey anti goat antibody (Jackson ImmunoResearch). Immunohistochemical analysis of 
CTGF (Santa Cruz Biotechnology Inc.) and MAC-2 was performed as described previously15,21. More than 10 
consecutive glomerular sections were examined for each mouse, and the mean number of MAC-2-positive cells 
per glomerular cross-section was calculated. For double immunofluorescence analysis of ZsGreen and podocin, 
PECAM1, PDGFRβ , Megalin, or AQP2, 10-μ m-thick cryostat sections fixed with 4% paraformaldehyde were 
incubated with Hylite Flour 555-labeled anti-podocin antibody, anti-PECAM1 antibody, anti-PDGFRβ antibody, 
anti-Megalin antibody, or anti-AQP2 antibody, respectively, for 1 h.
Cell line and glomerular RNA extraction and real-time RT-PCR. Quantitative real-time RT-PCR 
was performed using StepOnePlus system (Applied Biosystems, Foster City, CA) as described previously14. Ctgf, 
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Tgfb1, Acta2, Fn1, Itgav, Adgre1, Ccl2, Icam1, Vcam1, Mrc1, and Itgax mRNA expression levels were evaluated. 
Primers and probes sequences are listed in Supplementary Table 1. Data were normalized to Gapdh mRNA 
(TaqMan rodent Gapdh control reagents, Applied Biosystems).
Western blotting. Western blotting for CTGF and β -actin was performed as described previously43.
Flow cytometry analysis for bone marrow cells. Femurs of Pdgfra-ZsGreen mice were harvested and 
flushed through the ice cold phosphate-buffered saline. Bone marrow cell suspensions were passed through a 35 μ m 
cell strainer to obtain a single cell suspension48. Flow cytometric analysis and cell sorting were performed using 
fluorescence-activated cell sorter Aria II (BD biosciences), following the manufacturer’s instruction49.
Cell culture. A murine mesangial cell line, Mes13, was obtained from American Type Culture Collection 
(ATCC, Manassas, VA). Mes13 cells were cultured with Dulbecco’s Modified Eagle Medium (DMEM) containing 
high glucose/Nutrient Mixture F-12 Ham supplemented with 10% fetal bovine serum (FBS). Human umbilical 
vein endothelial cells (HUVEC) were cultured with EGMTM-2 BulletKitTM (Lonza, Basel, Switzerland). An adher-
ent macrophage cell line, Raw 264.7, was obtained from ATCC and were cultured with DMEM containing high 
glucose concentration with 10% FBS at 37 °C under 5% CO2. For the analysis for M1/M2 macrophage subtype 
transition by CTGF or TNF-α , RAW264.7 cells were stimulated with vehicle or 1000 ng/ml CTGF (PROSPEC, 
East Brunswick, NJ) in DMEM without FBS, and then harvested 3 h after stimulation. Stimulation with 10 ng/ml 
recombinant mouse TNF-α (R&D systems, Minneapolis, MA) was performed at the same protocol, and collected 
at 3 h. To examine mRNA expression of Ccl2 in mesangial cells, Mes 13 cell were stimulated with 1 ng/ml TGF-β 
1 and/or 500 ng/ml CTGF, and then harvested 3 h after stimulation.
Transfections with siRNA. Mes13 cells or HUVEC were transfected with 20 nM siRNA against mouse 
CTGF (#SI00190974, Qiagen, Germantown, MD) or human CTGF (#SI00029694, Qiagen) using Amaxa Cell 
Line Nucleofector Kit (Lonza)43, and then cultured for 48 h. Negative control siRNA (#SI1022076, Qiagen) was 
also used. The cells were stimulated with 5 ng/ml TGF-β 1 and/or 100 ng/ml recombinant CTGF. Cells were har-
vested 3 h after stimulation. Ccl2 mRNA expression was evaluated by TaqMan PCR.
Adhesion assay. Macrophage-mesangial cell binding assay was performed using the Vybrant cell adhesion 
assay Kit (Life technologies, Carlsbad, CA) according to the manufacturer’s instruction. Briefly, Mes13 cells or 
HUVEC transfected with siRNA against CTGF or control were cultured for 24 h in 96-well plates before pretreat-
ment with 10 ng/ml TNF-α . Twenty-four hours after TNF-α stimulation, Mes 13 cells or HUVEC were treated 
with 100 ng/ml human recombinant CTGF for 3 hours, and then were co-cultured with RAW264.7 cells (5 × 106 
cells/ml) which were pretreated with 5 μ M calcein-bis (carboxymethyl) aminomethyl (AM) solution in DMEM 
for 30 min. Two hours after co-culture, cells were washed four times with phosphate-buffered saline to remove 
non-adherent calcein-AM labeled Raw264.7 cells. Fluorescence intensity was measured using a 2030 ARVOTM X 
(PerkinElmer, Waltham, MA) at excitation and emission wavelengths of 485 nm and 535 nm, respectively.
Statistical analysis. Data are expressed as means ± s.e. Statistical analyses were performed using the 
Student’s t-test, the Tukey-Kramer test, or the Dunnett’s test using JMP9 statistical software (SAS institute, Cary, 
NC). P values less than 0.05 were considered statistically significant.
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